HOSMAC Spearheads One of North Maharashtra’s Most Ambitious Healthcare Projects

IMT News Desk
IMT News Desk
· 2 min read
HOSMAC spearheads the first phase of the 1,200-bed Tapanbhai Patel Memorial Hospital in Shirpur

HOSMAC has enabled the design and execution of the first phase of the 1,200-bed Tapanbhai Patel Memorial Hospital in Shirpur, marking a significant step forward for healthcare access in North Maharashtra.

The project, inaugurated by Maharashtra CM, Shri Devendra Fadnavis and is among the largest upcoming healthcare developments in the region. Developed under Shri Vile Parle Kelavani Mandal (SVKM), the hospital reflects a strong vision to bring advanced and accessible care closer to underserved communities.

Spread across 7 lakh sq. ft., this 1,200-bed facility is designed to reduce dependence on metro cities for specialised treatment. Once fully operational, it will serve not only Shirpur but also nearby regions such as Indore and Nashik, improving access to quality healthcare across geographies.

HOSMAC played a central role in the project, acting as the principal healthcare planning and project management partner. The firm led the project from concept to completion, covering key areas such as Schematic Space Planning, MEP Design, Medical Equipment Planning and Procurement Support, and Project Management Consulting.

Speaking on the project, Dr Vivek Desai, Founder and Managing Director, HOSMAC, said, “This project reflects our commitment to building healthcare infrastructure that improves access and supports communities at scale. The Shirpur facility shows how the right planning and execution can bring high-quality care closer to where it is needed most.”

The hospital initiative has been driven by the leadership of Mr. Amrish Patel, President of SVKM and former Education Minister of Maharashtra, along with Bhupesh Patel, whose vision has been key to bringing this project to life.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk